Pegylated liposomal doxorubicin treatment in patients with refractory or relapsed central nervous system (CNS) lymphoma.

被引：0
|
作者：
Calvisi, A [1 ]
Palmas, AD [1 ]
Lai, P [1 ]
Bianchi, A [1 ]
Murgia, A [1 ]
Gaviano, E [1 ]
Noli, AL [1 ]
Curreli, L [1 ]
Gabbas, A [1 ]
机构：
[1] San Francisco Hosp, Hematol & BMT Ctr, Nuoro, Italy
来源：
BLOOD | 2002年 / 100卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4750
引用
收藏
页码：302B / 303B
页数：2
相关论文
共 50 条
  • [21] Copanlisib in patients with relapsed or refractory follicular lymphoma.
    Dreyling, Martin H.
    Santoro, Armando
    Leppa, Sirpa
    Demeter, Judit
    Follows, George
    Lenz, Georg
    Kim, Won Seog
    Mollica, Luigina
    Nagler, Arnon
    Diong, Colin Phipps
    Provencio, Mariano
    Stevens, Don A.
    Trevarthen, David
    Magagnoli, Massimo
    Cupit, Lisa
    Yin, Shuxin
    Hiemeyer, Florian
    -Vargas, Jose E. Garcia
    Childs, Barrett H.
    Zinzani, Pier Luigi
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [22] High treatment related toxicity in patients with primary central nervous system lymphoma.
    Depil, S
    Guillerm, G
    Bauters, F
    Fenaux, P
    Quesnel, B
    [J]. BLOOD, 2000, 96 (11) : 236B - 236B
  • [23] New hopes in relapsed refractory primary central nervous system lymphoma
    Calimeri, Teresa
    Steidl, Carolina
    Fiore, Paolo
    Ferreri, Andres J. M.
    [J]. CURRENT OPINION IN ONCOLOGY, 2023, 35 (05) : 364 - 372
  • [24] Management of refractory or relapsed primary central nervous system lymphoma (Review)
    Yamanaka, Ryuya
    [J]. MOLECULAR MEDICINE REPORTS, 2009, 2 (06) : 879 - 885
  • [25] Rituximab monotherapy for relapsed or refractory primary central nervous system lymphoma
    Batchelor, T. T.
    Lesser, G. J.
    Grossman, S. A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [26] Sequential combination of gemcitabine, vinorelbine, pegylated liposomal doxorubicin and brentuximab as a bridge regimen to transplant in relapsed or refractory Hodgkin lymphoma
    Michallet, Anne-Sophie
    Guillermin, Yann
    Deau, Benedicte
    Lebras, Laure
    Harel, Stephanie
    Amorin, Sandy
    Reynes, Claire
    Salles, Gilles
    Subtil, Fabien
    Brice, Pauline
    [J]. HAEMATOLOGICA, 2015, 100 (07) : E269 - E271
  • [27] Histological verification of the treatment effect of tirabrutinib for relapsed/refractory primary central nervous system lymphoma
    Okita, Yoshiko
    Kano-Fujiwara, Rieko
    Nakatsuka, Shin-Ichi
    Honma, Keiichiro
    Kinoshita, Manabu
    [J]. EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2021, 10 (01)
  • [28] Histological verification of the treatment effect of tirabrutinib for relapsed/refractory primary central nervous system lymphoma
    Yoshiko Okita
    Rieko Kano-Fujiwara
    Shin-Ichi Nakatsuka
    Keiichiro Honma
    Manabu Kinoshita
    [J]. Experimental Hematology & Oncology, 10
  • [29] A retrospective study of efficacy and safety of mechlorethamine, vindesine, liposomal doxorubicin, and prednisone (MODP) in relapsed/refractory classical Hodgkin lymphoma.
    Zhou, Min-Hang
    Wang, Chunmeng
    Liu, Yang
    Ku, Wenjing
    Yang, Qingming
    Han, Weidong
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [30] A Phase I Study of Carfilzomib and Pegylated Liposomal Doxorubicin for Relapsed or Refractory Multiple Myeloma
    Keller, Jesse
    Fiala, Mark A.
    Sekhar, Jeevan
    Ceriotti, Connie
    Allen, Melissa
    Abboud, Camille N.
    Stockerl-Goldstein, Keith E.
    Wildes, Tanya M.
    Tomasson, Michael H.
    Vij, Ravi
    [J]. BLOOD, 2014, 124 (21)
12345